Stock XLS XLIFE SCIENCES AG
Add to a list
To use this feature you must be a member
Log inSign up

Xlife Sciences AG Stock BOERSE MUENCHEN

Equities

XLS

CH0461929603

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN
Other stock markets
 01:43:00 2022-02-10 pm EST 		5-day change 1st Jan Change
41.8 EUR -0.48% Intraday chart for Xlife Sciences AG -7.52% -3.69%
Feb. 05 Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership MT
2023 Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection MT

Financials

Sales 2023 * 800K 876K 825K Sales 2024 * 800K 876K 825K Capitalization 225M 247M 232M
Net income 2023 * -4M -4.38M -4.12M Net income 2024 * -4M -4.38M -4.12M EV / Sales 2023 * 361 x
Net Debt 2023 * 63.9M 69.94M 65.89M Net Debt 2024 * 65.2M 71.37M 67.23M EV / Sales 2024 * 363 x
P/E ratio 2023 *
-54.9 x
P/E ratio 2024 *
-59.8 x
Employees 13
Yield 2023 *
-
Yield 2024 *
-
Free-Float 49.77%
More Fundamentals * Assessed data

Chart Xlife Sciences AG

Dynamic Chart

Latest news about Xlife Sciences AG

Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership MT
Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection MT
Xlife Sciences to Sell Portfolio Company to 4D Lifetec MT
Xlife Sciences AG acquired 20% stake in 4D Lifetec AG for CHF 23.3 million. CI
Xlife Sciences Loss Narrows in H1; Revenue Declines MT
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Xlife Sciences AG Signs Memorandum of Understanding with the Regulator of the Healthcare Sector in the UAE, the Department of Health - Abu Dhabi CI
Xlife Sciences AG Announces Bernhard Scholz Will Not Stand for Re-Election CI
Xlife Sciences Posts Lower FY22 EPS; Revenue Increases MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Xlife Sciences Portfolio Company Receives European Patent for Biological Tissue Generation Method MT
Xlife Sciences' Portfolio Company To Research Therapy For Amyotrophic Lateral Sclerosis MT
Xlife Sciences AG Launches Project to Research a Potential Therapy for Amyotrophic Lateral Sclerosis CI
Xlife Sciences Portfolio Company Signs Exclusive License Agreement MT
Xlife Sciences Unit Taps CureDiab For Morbid Obesity Research MT
More news

Press releases Xlife Sciences AG

Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland EQ
Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City EQ
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline EQ
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases EQ
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases EQ
More press releases

News in other languages on Xlife Sciences AG

Xlife-Portfoliogesellschaft startet Kooperation mit T-Systems Schweiz
Xlife Sciences AG verkündet Kooperationsvertrag zwischen ihrer Portfolio-Gesellschaft FUSE-AI GmbH und T-Systems Schweiz
Xlife Sciences AG verkündet Kooperationsvertrag zwischen ihrer Portfolio-Gesellschaft FUSE-AI GmbH und T-Systems Schweiz
Bourse Zurich: légèrement dans le vert pour entamer la semaine
Xlife: Thermo Fischer rejoint un partenariat à Abou Dhabi
More news

Quotes and Performance

1 day-0.48%
Current month-3.69%
Current year-3.69%
More quotes

Highs and lows

3 years
41.80
Extreme 41.8
60.00
5 years
24.00
Extreme 24
60.00
10 years
24.00
Extreme 24
60.00
More quotes

Managers and Directors - Xlife Sciences AG

Managers TitleAgeSince
Oliver Baumann CEO
 Chief Executive Officer - 19-06-30
Carl von Halem DFI
 Director of Finance/CFO - 21-11-30
Alexander Zink CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Christian Faber CMP
 Compliance Officer - 19-09-11
Mark Müller BRD
 Director/Board Member - 18-10-24
Oliver Baumann CEO
 Chief Executive Officer - 19-06-30
More insiders

Company Profile

Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.
Sector
Biotechnology & Medical Research
Calendar
2024-04-22 - Q4 2023 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Xlife Sciences AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
39.5 CHF
Average target price
68 CHF
Spread / Average Target
+72.15%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.10% 42.07B
LONZA GROUP AG Stock Lonza Group AG
+50.98% 42.16B
MODERNA, INC. Stock Moderna, Inc.
+4.43% 39.77B
CELLTRION, INC. Stock Celltrion, Inc.
-11.36% 26.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.67% 24.68B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.84% 18.68B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.20% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.30% 11.99B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.91% 11.06B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. XLS Stock
  4. XLS Stock